Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axsome Thera (NQ: AXSM )

75.33 -1.47 (-1.91%)
Streaming Delayed Price Updated: 10:38 AM EDT, May 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Axsome Thera

< Previous 1 2 3 4 Next >
Rosen Law Firm Announces the Reopening of the Lead Plaintiff Appointment Process in a Class Action Against Axsome Therapeutics, Inc. and Certain Officers – AXSM
From The Rosen Law Firm, P.A.
Via Business Wire
Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics and the Global Alzheimer’s Disease Community Come Together in Raising Support for the Millions Affected by This Illness During Alzheimer’s Disease Awareness Month 2023
Axsome’s headquarters to be lit in teal as part of the Alzheimer’s Foundation of America awareness campaign 
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Present at Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer’s Disease Agitation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Conference
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Report Third Quarter 2023 Financial Results on November 6
Axsome to host conference call and webcast on Monday, Nov. 6, 2023, at 8:00 a.m. Eastern Time 
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Joins the National Alliance on Mental Illness and Others Advocating for the Importance of Mental Health on Mental Illness Awareness Week
From Axsome Therapeutics, Inc.
Via GlobeNewswire
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy Day
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Present at Three Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7
Axsome to host conference call and webcast on Monday, Aug. 7, 2023, at 8:00 a.m. Eastern Time 
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Announces Pricing of Public Offering of $225 Million of Shares of Common Stock
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Announces Proposed Public Offering of Common Stock
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Present New Sunosi® Data at SLEEP 2023
Cognitive improvement with Sunosi sustained over eight hours in patients with excessive daytime sleepiness due to obstructive sleep apnea 
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Present at the Bank of America Securities 2023 Healthcare Conference
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Joins Mental Health America and the State of New York to Raise Awareness of Mental Health During May is Mental Health Month
One World Trade Center to be lit up in green in observance of Mental Health Month 
From Axsome Therapeutics, Inc.
Via GlobeNewswire
NASDAQ: AXSM Shareholder Notice: Investigation over Potential Wrongdoing at Axsome Therapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 04/27/2023 -- Certain directors of Axsome Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties. 
Via SBWire
Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academy of
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8
Axsome to host conference call and webcast on Monday, May 8, 2023, at 8:00 a.m. Eastern Time 
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Present at Cowen’s 43rd Annual Health Care Conference
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe
From Axsome Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.